// App-Quantinova.ai

AB0954 (2018) : A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis

Researchers

Presenter

  • J. Hercogová

Principal Investigators

  • K.A. Papp

  • C.J. Edwards

  • V. Chyrok

  • T. Halady

  • M. Ullmann

  • P. Vlachos

Medical Centers

  • Charles Univ and VFN, Prague, Czech Republic

  • Probity Clinical Research, Waterloo, ON, Canada

  • University of Southampton, Southampton, UK

  • Fresenius Kabi, Aubonne

  • Cytel, Geneva, Switzerland

Locations

  • Czech Republic

  • Canada

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • MSB11022

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02660580

Sponsors

  • Fresenius Kabi

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved